Companion Animals

Cat Feline FIP Treatment Access

Improving access to FIP antiviral treatment globally is a critical welfare priority given the disease's historic universal fatality.

Key Facts

GS-441524 is effective for FIP but patent protection made it initially unavailable at affordable prices
Generic GS-441524 manufactured in China has dramatically reduced treatment costs for many owners
UK licensing of Veritas and Bova formulations has improved legal access in some markets
Treatment cost remains a barrier for many owners, particularly in lower-income countries
FIP support groups have created global networks to improve affordable treatment access

Welfare Considerations

Cats with FIP that cannot access affordable antiviral treatment face certain death from a disease that is now curable. Improving treatment access is one of the highest-impact feline welfare interventions available.

What You Can Do

Support FIP advocacy organizations working to improve access to affordable treatment
Donate to organizations providing subsidized GS-441524 to owners who cannot afford treatment
Advocate for affordable licensing of GS-441524 for veterinary use in all countries